الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
There are 30 patients were included in this study, each group contain about 15 patients .All patients was selected to be aged 15-60 years old and others was excluded .All patients was selected to be in low and intermediate sokal score according to age ,platelets counts ,spleen size and peripheral blasts cells.All patients received hydroxyurea as cytoreductive for few days to control white blood cells counts and the shift to gleveec for about (6-18 months ) until they reach complete cytogenetic response then they divided into two groups ,one group is continued on gleevec 400 mg and modified according to adverse effect ,and the second group received combination of gleevec 400 mg and weekly subcutaneous interferon in dose of 60 μg and modified according to adverse effect.
All patients who are non –Egyptians was excluded and who are in blastic crisis and accelerated phase was also excluded and Female patients who are pregnant was excluded.
All patients who are with organ toxicity grade II or impairment was excluded and those with performance status more than 1 also patients with active infection was excluded.
There were 15 patients in low sokal score and 15 patient was in intermediate sokal score .
8 patients went in cytogenetic response within 9 months and 2 patient went in complete cytogenetic response in 6 months and 8 patients went in complete cytogenetic response in 12 months and 12 patients went in complete cytogenetic response in 18 months.
Then all those patients divided into two group according to patients acceptance, each one 15 patients.
They are followed by CBC every 2-4 weeks and according to change in blood counts, and molecular asseement by quantitative PCR every 3 months.
In the 1st group the result show that 4 patients show disease progression by increase in the level of quintitave PCR of BCR-ABL.
Only one patient went in level of zero of BCR –ABL by PCR and remained in this level up till now.
5 patients remained in complete cytogenetic response without disease progression or disease improvement.
5 patient show improvement in level of BCR-ABL by PCR and increase in log reduction but didn’t reach zero level.
In other hand, the 2nd group (treatment of combination of interferon and gleevec) show 3 patients reached zero level of PCR-ABL by PCR.
3 patient shows no change in log reduction of BCR-ABL by PCR in spite of continues treatment without interruption, but maintain complete cytogenetic response without progression.
6 patient show improvements in log reduction from 2 log reduction to more than 3 log reduction.